Stay updated with breaking news from Biocon Biologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The company's consolidated revenue jumped 10% to Rs 1,945 crore in Q2FY22 on a year-on-year (YoY) basis, against Rs 1,765 crore in the corresponding quarter in the previous fiscal, Biocon said a regulatory filing.
Bengaluru (Karnataka) [India], Sep 17 (ANI): Biocon Biologics Ltd (BBL) and Serum Institute Life Sciences (SILS) have announced a strategic alliance in a bid to make a significant impact on global healthcare through vaccines and biologics.
Share this article Share this article PITTSBURGH and BENGALURU, India, July 28, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) today announced that the U.S. Food and Drug Administration (FDA) has approved Semglee ® (insulin glargine-yfgn) injection as the first interchangeable biosimilar product under the 351(k) regulatory pathway. Biocon Biologics Viatris CEO Michael Goettler commented: "We are extremely proud to achieve the industry's first approval of an interchangeable biosimilar product in the U.S., which will help broaden acces...
Biocon's Semglee gets USFDA approval; first interchangeable biosimilar product in US SECTIONS Last Updated: Jul 29, 2021, 09:56 AM IST Share Synopsis “It is a milestone achievement for both Biocon Biologics and our partner Viatris. This will allow pharmacy level substitution and thereby provide convenient and affordable access to Semglee, a quality Biosimilar Insulin Glargine,” Biocon Biologics, Executive Chairperson, Kiran Mazumdar-Shaw said in a statement. The company is eligible to have exclusivity for 12 months before the FDA can approve another biosimilar interchangeable to Lantus. B...
Biocon Biologics’ new monoclonal antibodies facility bags ISPE’s 2021 award April 28, 2021 × This is the first time that a biopharma company from India has been awarded an ISPE FOYA mention Biocon Biologics Ltd, a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon Ltd, has announced that it has been awarded with the 2021 Facility of the Year Award (FOYA) from the International Society for Pharmaceutical Engineering (ISPE). The company received an Honorable Mention award for its monoclonal antibodies drugs substances manufacturing facility located at Biocon...